<DOC>
	<DOCNO>NCT02324296</DOCNO>
	<brief_summary>ABSTRACT Objectives Combination chemotherapy active small cell lung cancer ( SCLC ) , although improvement overall survival ( OS ) do last 25 year , Cisplatin-Etoposide ( PE ) still consider world-wide standard , average median survival 7-8 month patient extended disease ( ED ) . In 1995 , randomize trial Hoosier Group 171 ED patient show significant advantage overall survival patient treat PEI ( Cisplatin , Etoposide Ifosfamide ) , compare PE . Despite , PEI regimen become commonly used regimen SCLC . Materials Methods Here present series 46 consecutive patient ( 30 male 16 female ) SCLC treat Institution PEI regimen : Cisplatin 20mg/m2 , Etoposide 75mg/m2 Ifosfamide 1200mg/m2 , day 1 4 , every 3 week . Patients receive total 219 cycle chemotherapy , mean 4,7 cycle per patient . Median age 63 ( range 59-70 ) ; performance status ( PS ) 0 29 patient ( 63 % ) , 1 13 patient ( 28 % ) 2 4 patient ( 9 % ) .</brief_summary>
	<brief_title>PEI REGIMEN : A Therapeutic Option Small Cell Lung Cancer ? A Monoinstitutional Experience 46 Consecutive Cases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>histologically cytologically proven SCLC measurable disease define RECIST criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>extend disease</keyword>
	<keyword>limited disease</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>etoposide</keyword>
	<keyword>ifosfamide</keyword>
</DOC>